These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21139484)

  • 1. Anti-vascular endothelial growth factor agents for pediatric retinal diseases.
    Wykoff CC; Houston SK; Berrocal AM
    Int Ophthalmol Clin; 2011; 51(1):185-99. PubMed ID: 21139484
    [No Abstract]   [Full Text] [Related]  

  • 2. The article by Kovach and Rosenfeld.
    Charbel Issa P; Holz FG; Scholl HP
    Retina; 2009 May; 29(5):717; author reply 717-8. PubMed ID: 19430284
    [No Abstract]   [Full Text] [Related]  

  • 3. Retinal anti-angiogenesis by a new route.
    Bicknell R
    Nat Biotechnol; 2008 May; 26(5):528-9. PubMed ID: 18464784
    [No Abstract]   [Full Text] [Related]  

  • 4. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern.
    Avery RL
    J AAPOS; 2009 Aug; 13(4):329-31. PubMed ID: 19683181
    [No Abstract]   [Full Text] [Related]  

  • 5. [Introduction].
    Piñero A
    Arch Soc Esp Oftalmol; 2012 Dec; 87 Suppl 1():1-2. PubMed ID: 23380434
    [No Abstract]   [Full Text] [Related]  

  • 6. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
    Waisbourd M; Goldstein M; Loewenstein A
    Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness.
    Brown G
    Curr Opin Ophthalmol; 2008 May; 19(3):175-6. PubMed ID: 18408489
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma.
    von Buelow M; Pape S; Hoerauf H
    Acta Ophthalmol Scand; 2007 Feb; 85(1):114-6. PubMed ID: 17244223
    [No Abstract]   [Full Text] [Related]  

  • 9. Juxtafoveal telangiectasias.
    Querques G; Delle Noci N
    Ophthalmology; 2008 Sep; 115(9):1636; author reply 1636. PubMed ID: 18762079
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of treatments given to patients before initiation of anti-vascular endothelial growth factor treatment.
    Hedaya J; Freeman WR
    Retina; 2008 Jun; 28(6):911-2; author reply 912. PubMed ID: 18536615
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravitreal bevacizumab for branch retinal vein occlusion.
    Spandau U; Wickenhäuser A; Rensch F; Jonas J
    Acta Ophthalmol Scand; 2007 Feb; 85(1):118-9. PubMed ID: 17244225
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab: one treatment for all the seasons?
    Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
    J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatments for macular degeneration: summarising evidence using network meta-analysis.
    Fadda V; Maratea D; Trippoli S; Messori A
    Br J Ophthalmol; 2011 Oct; 95(10):1476-7. PubMed ID: 21680571
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab and retinal ischemia.
    Neubauer AS; Kook D; Haritoglou C; Priglinger SG; Kampik A; Ulbig MW; Ceklic L
    Ophthalmology; 2007 Nov; 114(11):2096. PubMed ID: 17980746
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravitreal bevacizumab for vitreous haemorrhage.
    Jonas JB; Libondi T; von Baltz S; Vossmerbaeumer U
    Acta Ophthalmol; 2008 Aug; 86(5):585-6. PubMed ID: 18081904
    [No Abstract]   [Full Text] [Related]  

  • 16. [Angiogenesis suppressing therapy applied to malignant glioma].
    Takano S
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):941-7. PubMed ID: 19579331
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer.
    Díaz-Rubio E; Schmoll HJ
    Oncology; 2005; 69 Suppl 3():1-3. PubMed ID: 16301829
    [No Abstract]   [Full Text] [Related]  

  • 18. Bevacizumab: a potential agent for prevention and treatment of hypertrophic scar.
    Diao JS; Xia WS; Guo SZ
    Burns; 2010 Nov; 36(7):1136-7. PubMed ID: 20378254
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis.
    Akesbi J; Brousseaud FX; Adam R; Rodallec T; Nordmann JP
    Acta Ophthalmol; 2010 Mar; 88(2):e40-1. PubMed ID: 19508455
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic adverse events after bevacizumab.
    Roth DB; King A; Weiss M; Klein D
    Ophthalmology; 2009 Jun; 116(6):1226.e1. PubMed ID: 19486800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.